Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23622948 | 0.82 | F7 (0.51) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL20605026 | 0.82 | MYC (0.47) | HSD17B10CSNK2A2CSNK2BCSNK2A1F7 | |
| SCHEMBL30993539 | 0.78 | NR4A2 (0.36) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL31022882 | 0.78 | GABRA1 (0.42) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL20604918 | 0.77 | CYP1A2 (0.46) | GPR35CYP1A2ALDH1A1POLBMAPT | |
| SCHEMBL25369531 | 0.75 | CYP3A4 (0.41) | AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1 | |
| SCHEMBL3762044 | 0.74 | KDM4E (0.50) | HSD17B10CSNK2A2CSNK2BCSNK2A1CYP1A2 | |
| SCHEMBL23138185 | 0.71 | SLC22A6 (0.46) | HSD17B10KDM4EALDH1A1POLBMAPT | |
| SCHEMBL9288270 | 0.71 | AKR1C3 (0.39) | AKR1C4AKR1C3AKR1C2AKR1C1HSD17B10 | |
| SCHEMBL5079577 | 0.71 | KMT2A (0.51) | HSD17B10KDM4EALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891386-B2 | Indole compounds and their use | ARIAGEN, INC. (CA) | 2024-02-06 | — | — | US | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230054194-A1 | Methods of Treating Cancer | ARIAGEN, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11459322-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11427576-B2 | Indole compounds and their use | ARIAGEN, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3883605-A1 | METHODS OF TREATING CANCER | Ariagen, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210179604-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200354353-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3713937-A2 | INDOLE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS | Ariagen, Inc. (US) | 2020-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179604-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | AKR1C4 2948/4885AKR1C3 2231/4885AKR1C2 2725/4885 |
| US-11459322-B2 | Indole compounds and their use | IDO1, IDO2, INMT | AKR1C4 2948/4885AKR1C3 2231/4885AKR1C2 2725/4885 |
| US-20200354353-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | AKR1C4 2948/4885AKR1C3 2231/4885AKR1C2 2725/4885 |
| US-11427576-B2 | Indole compounds and their use | IDO1, IDO2, INMT | AKR1C4 2948/4885AKR1C3 2231/4885AKR1C2 2725/4885 |
| US-11891386-B2 | Indole compounds and their use | IDO1, IDO2, INMT | AKR1C4 2948/4885AKR1C3 2231/4885AKR1C2 2725/4885 |
| US-20230054194-A1 | Methods of Treating Cancer | TP53, MSH2, PDCD1 | AKR1C4 4315/4885AKR1C3 4110/4885AKR1C2 4206/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | AKR1C4 2948/4885AKR1C3 2231/4885AKR1C2 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.